All diseases
Disease workspace
COVID-19
Acute respiratory disease caused by SARS-CoV-2 with variable severity and systemic inflammation.
Unmet need
Effective outpatient and hospitalized therapies; long COVID management.
Immune hyperactivationCoagulationACE2 axis
Evidence behind this
Confidence score91%
Signal strength: HighLevel 1 (large RCT)
Evidence grade
Strong Repurposing Signal
28-day mortality reduction in patients requiring oxygen; no benefit in mild disease.
Mechanism
Glucocorticoid-mediated suppression of cytokine storm in severe COVID-19.
clinical trialmeta analysisPhase III (platform trial)
Authoritative sources
AI-generated summary
Generated March 15, 2026Last verified June 22, 2026
The RECOVERY trial provided definitive evidence for dexamethasone 6 mg daily in hospitalized COVID-19 patients on supplemental oxygen or ventilation. WHO and NIH guidelines endorse this indication.
Source papers
- RECOVERY Collaborative Group, NEJM 2021
This summary is AI-assisted and human-reviewed. It does not constitute medical advice. Always consult authoritative sources and qualified professionals.